Immunity against MOPC 104E plasmacytoma: effects of tumor size and time post therapy on in vivo tumor immunity.

No abstract is available for this paper.

• Publication year

  1978

• Venue

  Journal of the National Cancer Institute

• Publication date

  1978-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/JNCI/60.5.1107PMID 642029
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Kinetics of the response of spleen cells from tumor‐bearing animals in an in vivo tumor neutralization assay

  1976cited by this paper
• Initiation and evolution of antitumor immunity to a transplanted murine lymphosarcoma.

  1976cited by this paper
• Cell-mediated immunity to Friend virus-induced leukemia. III. Characteristics of secondary cell-mediated cytotoxic response.

  1976cited by this paper
• Non-adaptive rejection of small tumour inocula as a model of immune surveillance

  1976cited by this paper
• Development of two manifestations of T-lymphocyte reactivity during tumor growth: altered kinetics associated with elevated growth rates.

  1975cited by this paper
• Specific immunoprotection with 3 M KCl solubilized tumor antigen.

  1975cited by this paper
• Myeloma proteins as tumor-specific antigens.

  1975cited by this paper
• Biologic effects of solubilized H-2 and tumor-specific antigens.

  1975cited by this paper
• Cellular and viral antigens of BALB-c myeloma.

  1974cited by this paper
• Quantitation of total-body tumor cells (MOPC 104E). I. Subcutaneous tumor model.

  1974cited by this paper
• Quantitation of total-body tumor cells (MOPC 104E). II. Ascites tumor model.

  1974cited by this paper
• Cell interactions in adoptive immune rejection of a syngeneic tumor

  1974cited by this paper
• Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma.

  1974cited by this paper
• Immunogenicity, antigenicity and mechanisms of tumor rejection of mineral‐oil‐induced plasmacytomas in syngeneic BALB/c mice

  1974cited by this paper
• Combination chemotherapy of advanced murine myeloma and subsequent resistance to tumor cell challenge.

  1974cited by this paper
• THE LYMPHOCYTE RESPONSE TO PRIMARY MOLONEY SARCOMA VIRUS TUMORS IN BALB/c MICE

  1973cited by this paper
• Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors.

  1973cited by this paper
• The effect of tumor size on concomitant tumor immunity.

  1973cited by this paper
• [Induction of an immunity against plasma cell sarcoma graft in the mouse BALB-c].

  1969cited by this paper
• A simplified method of evaluating dose-effect experiments.

  1948cited by this paper

• Tumor Proliferation and Chemotherapy in Immunosuppressed Mice1

  2006cites this paper
• Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.

  2000cites this paper
• Augmentation of Natural Immunity and Regulation of Tumor Growth by Conditioning a

  1988cites this paper
• Immunity and its role in conventional cancer therapy.

  1985cites this paper
• Enhancement of phagocytosis by different anti-neoplastic drugs.

  1985cites this paper
• Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. II. Enhancement of in vitro cell-mediated cytotoxicity by combined chemotherapy-immunotherapy.

  1985cites this paper
• Tumor proliferation and chemotherapy in immunosuppressed mice.

  1983cites this paper
• Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.

  1982cites this paper
• Maintenance of MOPC 104E myeloma in plateau phase.

  1980cites this paper
• Tumor immunity against MOPC 104E: leukocyte adherence inhibition (L.A.I.) assay.

  1980cites this paper
• Tumor Leukocyte Adherence Assay* Immunity Against MOPC 104E: Inhibition (L.A.I.)

  1980cites this paper
• Therapy of the murine plasmacytoma MOPC 104E: role of the immune response.

  1978cites this paper